Compared to current HCC therapies that offer only minimal improvements in overall survival, niclosamide offers promise as a cancer multitool compound due to its ability to decrease the AR/AR-SV protein and prevent rebound oncogenic signaling through its activity against NF-κB, STAT3, and KRAS. Here, NFKB1 is linked to cancer.